Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138690 | Leukemia Research | 2009 | 7 Pages |
Abstract
Soluble CD83 (sCD83), a potent immunosuppressive agent, circulates at elevated levels in some chronic lymphocytic leukemia (CLL) patients. We report that CLL patients with elevated plasma sCD83 levels had significantly shorter (P = 0.038) treatment free survival. Culture of CLL cells with solid phase CD83 mAb + IL-4 significantly increases sCD83 release (23–117-fold, P = 0.013) and ligation of normal donor PBMC with solid phase CD83 mAb alone induces similar significant increases in sCD83 release (P = 0.003). RT-PCR analysis detected the presence of a transcript for sCD83 in 2/3 CLL samples. These results suggest sCD83 release may play a regulatory role in CLL progression.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
B.D. Hock, L.J. Fernyhough, S.M. Gough, A. Steinkasserer, A.G. Cox, J.L. McKenzie,